Santhera Pharmaceuticals Holding AG (SWX:SANN)
Switzerland · Delayed Price · Currency is CHF 10.22
-0.30 (-2.85%)
Oct 21, 2025, 5:31 PM CET
SWX:SANN Income Statement
Financials in millions CHF. Fiscal year is January - December.
Millions CHF. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 49.02 | 39.12 | 103.41 | 7.47 | -1.6 | 15.01 | Upgrade | |
Revenue Growth (YoY) | -56.85% | -62.17% | 1283.84% | - | - | -80.09% | Upgrade |
Cost of Revenue | 42.44 | 15.53 | 3.24 | 3.59 | 3.77 | 10.43 | Upgrade |
Gross Profit | 6.57 | 23.58 | 100.18 | 3.88 | -5.36 | 4.58 | Upgrade |
Selling, General & Admin | 33.21 | 30.5 | 30.97 | 25.42 | 22.06 | 23.91 | Upgrade |
Research & Development | 24.39 | 26.47 | 18.67 | 24.33 | 29.72 | 34.23 | Upgrade |
Other Operating Expenses | -0.18 | -0.23 | -0.62 | -0.1 | -0.25 | -0.49 | Upgrade |
Operating Expenses | 57.43 | 56.73 | 49.02 | 49.65 | 51.53 | 57.65 | Upgrade |
Operating Income | -50.85 | -33.15 | 51.16 | -45.77 | -56.89 | -53.08 | Upgrade |
Interest Expense | -8.55 | -7.78 | -21.31 | -20.19 | -16.42 | -6.89 | Upgrade |
Interest & Investment Income | 0.8 | 0.93 | 0.51 | - | 0 | 0 | Upgrade |
Currency Exchange Gain (Loss) | -2.03 | 2.83 | -1.15 | -0.22 | -0.06 | 0.27 | Upgrade |
Other Non Operating Income (Expenses) | -4.73 | -4.52 | 7.51 | -0.35 | 5.22 | -7.76 | Upgrade |
EBT Excluding Unusual Items | -65.35 | -41.69 | 36.71 | -66.53 | -68.16 | -67.46 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | 0.68 | - | - | - | Upgrade |
Gain (Loss) on Sale of Assets | 0.04 | 0.04 | 17.68 | - | - | - | Upgrade |
Asset Writedown | - | - | - | -6.21 | - | - | Upgrade |
Other Unusual Items | -0.02 | -0.02 | -0.25 | 2.12 | 13.44 | - | Upgrade |
Pretax Income | -65.33 | -41.66 | 54.82 | -70.62 | -54.72 | -67.46 | Upgrade |
Income Tax Expense | 0.21 | 0.31 | 0.04 | 0.46 | 0.81 | 0.2 | Upgrade |
Net Income | -65.54 | -41.97 | 54.78 | -71.08 | -55.53 | -67.66 | Upgrade |
Net Income to Common | -65.54 | -41.97 | 54.78 | -71.08 | -55.53 | -67.66 | Upgrade |
Shares Outstanding (Basic) | 12 | 11 | 11 | 6 | 3 | 1 | Upgrade |
Shares Outstanding (Diluted) | 12 | 11 | 11 | 6 | 3 | 1 | Upgrade |
Shares Change (YoY) | 9.97% | 4.24% | 79.29% | 78.31% | 156.61% | 21.15% | Upgrade |
EPS (Basic) | -5.41 | -3.69 | 5.18 | -11.67 | -16.25 | -50.81 | Upgrade |
EPS (Diluted) | -5.42 | -3.69 | 5.01 | -11.67 | -16.25 | -50.81 | Upgrade |
Free Cash Flow | -41.06 | -35.68 | 47.18 | -29.9 | -37.36 | -43.54 | Upgrade |
Free Cash Flow Per Share | -3.39 | -3.13 | 4.32 | -4.91 | -10.93 | -32.70 | Upgrade |
Gross Margin | 13.41% | 60.29% | 96.87% | 51.93% | - | 30.50% | Upgrade |
Operating Margin | -103.75% | -84.75% | 49.47% | -612.42% | - | -353.65% | Upgrade |
Profit Margin | -133.72% | -107.30% | 52.97% | -951.10% | - | -450.82% | Upgrade |
Free Cash Flow Margin | -83.78% | -91.21% | 45.62% | -400.05% | - | -290.11% | Upgrade |
EBITDA | -45.63 | -27.99 | 53.76 | -42.56 | -53.59 | -49.62 | Upgrade |
EBITDA Margin | -93.09% | -71.56% | 51.99% | - | - | - | Upgrade |
D&A For EBITDA | 5.22 | 5.16 | 2.6 | 3.21 | 3.3 | 3.46 | Upgrade |
EBIT | -50.85 | -33.15 | 51.16 | -45.77 | -56.89 | -53.08 | Upgrade |
EBIT Margin | -103.75% | -84.75% | 49.47% | - | - | - | Upgrade |
Effective Tax Rate | - | - | 0.07% | - | - | - | Upgrade |
Revenue as Reported | 49.02 | 39.12 | 103.41 | 7.47 | -1.6 | 15.01 | Upgrade |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.